+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viral Vector Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • PDF Icon

    Report

  • 150 Pages
  • July 2024
  • Region: Global
  • DelveInsight
  • ID: 5985212
The global viral vector manufacturing market was valued at USD 696.17 million in 2023, growing at a CAGR of 19.22% during the forecast period from 2024 to 2030 to reach USD 1.99 billion by 2030. The demand for viral vector manufacturing is primarily being boosted by the rising cases of serious genetic disorders such as spinal muscular atrophy, hemophilia, retinitis pigmentosa, and others, the rising incidence for different cancer types, increasing popularity and research on gene and cell therapy, and growing concern over sudden occurrence of epidemics and pandemics are further contributing in the overall growth of the viral vector manufacturing market during the forecast period from 2024-2030.

Viral Vector Manufacturing Market Dynamics:

The increasing number of individuals with genetic disorders who are provided with treatment in form of gene and cell therapy via the utilization of viral vectors is the major factor driving the growth of the viral vector manufacturing market. As per the report published by the World Federation of Hemophilia 2022, globally about 347,026 people were reported to be suffering from bleeding disorders in 2020. As per the same source in 2020, nearly around 209,614 people had hemophilia which includes 165,379 cases of hemophilia A, 33,076 cases of hemophilia B, and 11,159 cases of hemophilia type unknown or type not reported.

The above-mentioned source further stated that 84,197 were reported to have Von Willebrand disease and 53,215 people were suffering from other bleeding disorders across the world in 2020.

Also, owing to various advantages such as high gene transduction efficiency, precise delivery of genes to target cells, induction of robust immune responses, and increased cellular immunity among others offered by viral vectors, they are considered an attractive and appropriate vehicle for cancer therapy which is crucial in managing the rising incidence of different cancer types such as blood cancer, bladder cancer, and others. For instance, the data published by Global Cancer Observatory 2022 says that globally around 544,352 cases of Non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. Kymriah by Novartis AG is a lentiviral vector-based gene therapy treatment and the first chimeric antigen receptor (CAR) T cell immunotherapy. Kymriah is approved by the US Food and Drug Administration and is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma.

However, biosafety issues associated with viral vectors and challenges associated with the manufacturing of viral vectors may restrict the growth of the overall viral vector manufacturing market.

The COVID-19 pandemic had a positive impact on the market for viral vector manufacturing. Due to the surge in the number of patients with COVID-19, the number of biotech and pharmaceutical companies backed by the government and other prominent organizations across the world were highly focused on developing solutions in form of vaccines against COVID-19. Later, companies like AstraZeneca and Johnson and Johnson developed COVID-19 vaccines that involved the usage of viral vectors. Apart from these, many other companies are largely involved in the development of viral vector-based vaccines for various other indications. Nevertheless, the viral vector manufacturing market is expected to witness positive growth in the upcoming years.

Viral Vector Manufacturing Market Segment Analysis:

Viral vector manufacturing market by Type (Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, and Others), By Application (Gene Therapy, Cell Therapy, and Vaccines), By End-User (Research Organizations, Biotech And Pharmaceutical Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the vector type segment of the viral vector manufacturing market, the adenoviral vectors category is expected to amass a significant revenue share in the year 2023. This can be attributed to the advantages and applications associated with adenovirus vectors.

Adenoviral vectors have many advantages over other viral vectors, including a wide range of tissue tropism, a well-characterized genome, ease of genetic manipulation, acceptance of large transgene DNA insertions that can be up to 8 kilobases, inherent adjuvant properties, capacity to incite robust transgene-specific T cell and antibody responses, non-replicative host nature, and simplicity of large-scale production.

Adenovirus is known for its high transduction efficiency. They facilitate a high level of gene expression by delivering multiple copies of the genome into one host cell. These can transduce both dividing and non-dividing cells.

Adenoviruses are mostly preferred as gene therapy vectors because the virions are taken up efficiently by cells in vivo. Also, the vaccines derived from adenoviruses that are used in humans are said to have no reported side effects. AstraZeneca's COVID-19 Vaccine and Janssen's (Johnson & Johnson) COVID-19 vaccine are based on an adenoviral vector.

Therefore, considering the advantages associated with adenoviral vectors and their growing usage, this category is expected to generate considerable revenue thereby pushing the overall growth of the global viral vector manufacturing market during the forecast period.

North America is expected to dominate the overall Viral Vector Manufacturing Market:

Among all the regions, North America is estimated to account for the largest share of the viral vector manufacturing market in the year 2023. Owing to the significance of key growth factors such as the increasing patient population suffering from genetic disorders, the rising incidence of cancer, sophisticated healthcare infrastructure, the presence of key players, and fast regulatory approval for new products, the market for viral vector manufacturing is expected to register significant growth in the region.

According to National Center on Birth Defects and Developmental Disabilities under the Centers for Disease Control and Prevention (CDC) 2022, sickle cell anemia affects about 100,000 Americans. As per the same source, Hemophilia A affects 1 in 5,000 male births and each year about 400 babies are born with hemophilia A in the United States.

The data published by CDC 2022 says that every year 57,000 men and 18,000 women get bladder cancer in the United States. As per Global Cancer Observatory 2020, about 80.6 thousand cases of bladder cancer were reported in the US in 2020 and by 2040 this number is expected to reach 122 thousand.

Additionally, various strategic activities on viral vector manufacturing in the United States are also anticipated to expand the viral vector manufacturing market during the given forecast period. For example, in October 2022, Kite, a Gilead Company announced that the US FDA has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.

Hence, the above-mentioned factors are going to increase the growth of the viral vector manufacturing market in the region.

Viral Vector Manufacturing Market Key Players:

Some of the key market players operating in the viral vector manufacturing market include Oxford Biomedica, Thermo Fisher Scientific Inc., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others.

Recent Developmental Activities in the Viral Vector Manufacturing Market:

  • In August 2022, Thermo Fisher Scientific, the world leader in serving science, expanded its cell and gene therapy capabilities with the opening of its new viral vector manufacturing facility in Plainville, Mass.
  • In October 2022, Merck, a leading science and technology company, announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint.

Key Takeaways from the Viral Vector Manufacturing Market Report Study

  • Market size analysis for current viral vector manufacturing market size (2023), and market forecast for 6 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the viral vector manufacturing market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global viral vector manufacturing market.
  • Various opportunities available for the other competitor in the viral vector manufacturing market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current viral vector manufacturing market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for viral vector manufacturing market growth in the coming future?

Target Audience who can be benefited from this Viral Vector Manufacturing Market Report Study

  • Viral Vector Manufacturing products providers
  • Research organizations and consulting companies
  • Viral Vector Manufacturing- related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in viral vector manufacturing
  • Various End-users who want to know more about the viral vector manufacturing market and the latest innovations and developments in the viral vector manufacturing market.

Frequently Asked Questions for the Viral Vector Manufacturing Market:

1. What are viral vectors?

Viral vectors are tools in molecular biology that have been designed and developed for the efficient and safe delivery of genetic materials into cells.

2. What is the market for global viral vector manufacturing?

The global viral vector manufacturing market was valued at USD 696.17 million in 2023, growing at a CAGR of 19.22% during the forecast period from 2024 to 2030 to reach USD 1.99 billion by 2030.

3. What are the drivers for the global viral vector manufacturing market?

The growth of the viral vector manufacturing market is primarily being boosted by the increasing importance of viral vectors in gene and cell therapy, the increasing number of patients with genetic disorders, the rising incidence of cancer, and rising research and development activities related to viral vector manufacturing are contributing to the overall growth of the viral vector manufacturing market during the forecast period from 2024-2030.

4. Who are the key players operating in the global viral vector manufacturing market?

Some of the key market players operating in the viral vector manufacturing market include Oxford Biomedica, Thermo Fisher Scientific Inc., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others.

5. Which region has the highest share in the viral vector manufacturing market?

North America is expected to dominate the overall viral vector manufacturing market during the forecast period from 2024-2030. Factors such as the increasing patient population suffering from genetic disorders, the rising incidence of cancer, sophisticated healthcare infrastructure, the presence of key players, and the set-up of new viral vector manufacturing facilities, among others, are driving the growth of the viral vector manufacturing market in the region.


This product will be delivered within 2 business days.

Table of Contents

1. Viral Vector Manufacturing Market Report Introduction
2. Viral Vector Manufacturing Market Executive Summary
2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
3. Regulatory Analysis
3.1. The United States
3.2. Europe
3.3. Japan
3.4. China
4. Viral Vector Manufacturing Market Key Factors Analysis
4.1. Viral Vector Manufacturing Market Drivers
4.1.1. The surge in the number of patients with genetic disorders
4.1.2. Increasing incidences of epidemics and pandemics
4.1.3. The growing importance of viral vectors in cancer therapy
4.2. Viral Vector Manufacturing Market Restraints and Challenges
4.2.1. Biosafety issues associated with viral vectors
4.2.2. Challenges associated with the manufacturing of viral vectors
4.3. Viral Vector Manufacturing Market Opportunities
4.3.1. Increased R&D and investments in viral vectors
4.3.2. Development of flexible and scalable technologies for viral vector manufacturing
5. Viral Vector Manufacturing Market Porter’s Five Forces Analysis
5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry
6. COVID-19 Impact Analysis on the Viral Vector Manufacturing Market
7. Viral Vector Manufacturing Market Layout
7.1. By Type
7.1.1. Adenoviral Vectors
7.1.2. Adeno-Associated Viral (AAV) Vectors
7.1.3. Lentiviral Vectors
7.1.4. Others
7.2. By Application
7.2.1. Gene Therapy
7.2.2. Cell Therapy
7.2.3. Vaccines
7.3. By End-User
7.3.1. Research Organizations
7.3.2. Biotech and Pharmaceutical Companies
7.3.3. Others
7.4. By Geography
7.4.1. North America Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.1.1. United States Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.1.2. Canada Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.1.3. Mexico Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.2. Europe Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.2.1. France Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.2.2. Germany Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.2.3. United Kingdom Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.2.4. Italy Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.2.5. Spain Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.2.6. Rest of Europe Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.3. Asia-Pacific Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.3.1. China Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.3.2. Japan Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.3.3. India Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.3.4. Australia Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.3.5. South Korea Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.3.6. Rest of Asia-Pacific Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.4. Rest of the World (RoW) Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.4.1. Middle East Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.4.2. Africa Viral Vector Manufacturing Market Size in USD million (2021-2030)
7.4.4.3. South America Viral Vector Manufacturing Market Size in USD million (2021-2030)
8. Viral Vector Manufacturing Market Company and Product Profiles
8.1. Thermo Fisher Scientific Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Financial Overview
8.1.4. Product Listing
8.1.5. Entropy
8.2. PerkinElmer Inc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Financial Overview
8.2.4. Product Listing
8.2.5. Entropy
8.3. Oxford Biomedica
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Financial Overview
8.3.4. Product Listing
8.3.5. Entropy
8.4. Charles River Laboratories
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Financial Overview
8.4.4. Product Listing
8.4.5. Entropy
8.5. FUJIFILM Diosynth Biotechnologies
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Financial Overview
8.5.4. Product Listing
8.5.5. Entropy
8.6. Batavia Biosciences
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Financial Overview
8.6.4. Product Listing
8.6.5. Entropy
8.7. CEVEC Pharmaceuticals GmbH
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Financial Overview
8.7.4. Product Listing
8.7.5. Entropy
8.8. REGENXBIO Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Financial Overview
8.8.4. Product Listing
8.8.5. Entropy
8.9. BioNTech IMFS
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Financial Overview
8.9.4. Product Listing
8.9.5. Entropy
8.10. AGC Biologics
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Financial Overview
8.10.4. Product Listing
8.10.5. Entropy
8.11. ANDELYN Biosciences
8.11.1. Company Overview
8.11.2. Company Snapshot
8.11.3. Financial Overview
8.11.4. Product Listing
8.11.5. Entropy
8.12. INSTITUT MERIEUX
8.12.1. Company Overview
8.12.2. Company Snapshot
8.12.3. Financial Overview
8.12.4. Product Listing
8.12.5. Entropy
8.13. IDT Biologika
8.13.1. Company Overview
8.13.2. Company Snapshot
8.13.3. Financial Overview
8.13.4. Product Listing
8.13.5. Entropy
8.14. Lonza
8.14.1. Company Overview
8.14.2. Company Snapshot
8.14.3. Financial Overview
8.14.4. Product Listing
8.14.5. Entropy
8.15. Genezen
8.15.1. Company Overview
8.15.2. Company Snapshot
8.15.3. Financial Overview
8.15.4. Product Listing
8.15.5. Entropy
8.16. NecstGen.
8.16.1. Company Overview
8.16.2. Company Snapshot
8.16.3. Financial Overview
8.16.4. Product Listing
8.16.5. Entropy
8.17. Avid Bioservices Inc.
8.17.1. Company Overview
8.17.2. Company Snapshot
8.17.3. Financial Overview
8.17.4. Product Listing
8.17.5. Entropy
8.18. Takara Bio Inc.
8.18.1. Company Overview
8.18.2. Company Snapshot
8.18.3. Financial Overview
8.18.4. Product Listing
8.18.5. Entropy
8.19. Merck & Co., Inc.
8.19.1. Company Overview
8.19.2. Company Snapshot
8.19.3. Financial Overview
8.19.4. Product Listing
8.19.5. Entropy
8.20. VIROCELL BIOLOGICS LTD.
8.20.1. Company Overview
8.20.2. Company Snapshot
8.20.3. Financial Overview
8.20.4. Product Listing
8.20.5. Entropy
9. KOL Views10. Project Approach11. About the Publisher12. Disclaimer
List of Tables
Table 1: Competitive Analysis
Table 2: COVID-19 Impact Analysis
Table 3: Viral Vector Manufacturing Market in Global (2021-2030)
Table 4: Viral Vector Manufacturing Market in Global by Type (2021-2030)
Table 5: Viral Vector Manufacturing Market in Global by Application (2021-2030)
Table 6: Viral Vector Manufacturing Market in Global by End-User (2021-2030)
Table 7: Viral Vector Manufacturing Market in Global by Geography (2021-2030)
Table 8: Viral Vector Manufacturing Market in North America (2021-2030)
Table 9: Viral Vector Manufacturing Market in North America by Country (2021-2030)
Table 10: Viral Vector Manufacturing Market in the US (2021-2030)
Table 11: Viral Vector Manufacturing Market in Canada (2021-2030)
Table 12: Viral Vector Manufacturing Market in Mexico (2021-2030)
Table 13: Viral Vector Manufacturing Market in Europe (2021-2030)
Table 14: Viral Vector Manufacturing Market in Europe by Country (2021-2030)
Table 15: Viral Vector Manufacturing Market in France (2021-2030)
Table 16: Viral Vector Manufacturing Market in Germany (2021-2030)
Table 17: Viral Vector Manufacturing Market in the United Kingdom (2021-2030)
Table 18: Viral Vector Manufacturing Market in Italy (2021-2030)
Table 19: Viral Vector Manufacturing Market in Spain (2021-2030)
Table 20: Viral Vector Manufacturing Market in the Rest of Europe (2021-2030)
Table 21: Viral Vector Manufacturing Market in Asia-Pacific (2021-2030)
Table 22: Viral Vector Manufacturing Market in Asia-Pacific by Country (2021-2030)
Table 23: Viral Vector Manufacturing Market in China (2021-2030)
Table 24: Viral Vector Manufacturing Market in Japan (2021-2030)
Table 25: Viral Vector Manufacturing Market in India (2021-2030)
Table 26: Viral Vector Manufacturing Market in Australia (2021-2030)
Table 27: Viral Vector Manufacturing Market in South Korea (2021-2030)
Table 28: Viral Vector Manufacturing Market in Rest of Asia-Pacific (2021-2030)
Table 29: Viral Vector Manufacturing Market in the Rest of the World (2021-2030)
Table 30: Viral Vector Manufacturing Market in RoW by Region (2021-2030)
Table 31: Viral Vector Manufacturing Market in the Middle East (2021-2030)
Table 32: Viral Vector Manufacturing Market in Africa (2021-2030)
Table 33: Viral Vector Manufacturing Market in South America (2021-2030)
List of Figures
Figure 1: Competitive Analysis
Figure 2: COVID-19 Impact Analysis
Figure 3: Viral Vector Manufacturing Market in Global (2021-2030)
Figure 4: Viral Vector Manufacturing Market in Global by Type (2021-2030)
Figure 5: Viral Vector Manufacturing Market in Global by Application (2021-2030)
Figure 6: Viral Vector Manufacturing Market in Global by End-User (2021-2030)
Figure 7: Viral Vector Manufacturing Market in Global by Geography (2021-2030)
Figure 8: Viral Vector Manufacturing Market in North America (2021-2030)
Figure 9: Viral Vector Manufacturing Market in North America by Country (2021-2030)
Figure 10: Viral Vector Manufacturing Market in the US (2021-2030)
Figure 11: Viral Vector Manufacturing Market in Canada (2021-2030)
Figure 12: Viral Vector Manufacturing Market in Mexico (2021-2030)
Figure 13: Viral Vector Manufacturing Market in Europe (2021-2030)
Figure 14: Viral Vector Manufacturing Market in Europe by Country (2021-2030)
Figure 15: Viral Vector Manufacturing Market in France (2021-2030)
Figure 16: Viral Vector Manufacturing Market in Germany (2021-2030)
Figure 17: Viral Vector Manufacturing Market in the United Kingdom (2021-2030)
Figure 18: Viral Vector Manufacturing Market in Italy (2021-2030)
Figure 19: Viral Vector Manufacturing Market in Spain (2021-2030)
Figure 20: Viral Vector Manufacturing Market in the Rest of Europe (2021-2030)
Figure 21: Viral Vector Manufacturing Market in Asia-Pacific (2021-2030)
Figure 22: Viral Vector Manufacturing Market in Asia-Pacific by Country (2021-2030)
Figure 23: Viral Vector Manufacturing Market in China (2021-2030)
Figure 24: Viral Vector Manufacturing Market in Japan (2021-2030)
Figure 25: Viral Vector Manufacturing Market in India (2021-2030)
Figure 26: Viral Vector Manufacturing Market in Australia (2021-2030)
Figure 27: Viral Vector Manufacturing Market in South Korea (2021-2030)
Figure 28: Viral Vector Manufacturing Market in Rest of Asia-Pacific (2021-2030)
Figure 29: Viral Vector Manufacturing Market in the Rest of the World (2021-2030)
Figure 30: Viral Vector Manufacturing Market in RoW by Region (2021-2030)
Figure 31: Viral Vector Manufacturing Market in the Middle East (2021-2030)
Figure 32: Viral Vector Manufacturing Market in Africa (2021-2030)
Figure 33: Viral Vector Manufacturing Market in South America (2021-2030)
Figure 34: Market Drivers
Figure 35: Market Barriers
Figure 36: Marker Opportunities
Figure 37: PORTER'S Five Force Analysis

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Oxford Biomedica
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories
  • FUJIFILM Diosynth Biotechnologies
  • Batavia Biosciences
  • CEVEC Pharmaceuticals GmbH
  • REGENXBIO Inc.
  • BioNTech IMFS
  • AGC Biologics
  • ANDELYN BIOSCIENCES
  • INSTITUT MERIEUX
  • IDT Biologika
  • Lonza
  • Genezen
  • NecstGen
  • Avid Bioservices, Inc.
  • Takara Bio Inc.
  • VIROCELL BIOLOGICS, LTD